Five months after signing a consent decree with the FDA, Ranbaxy Laboratories has again run afoul of regulators. This time, the drugmaker was issued a four-day suspension that prevents it from selling, manufacturing or marketing its products in the state of Maharashtra in India.
FULL ARTICLE AT Pharmalot